Abstract
Constitutive overexpression of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal aberration t(2;5)(p23;q35). Proteins that interact with ALK tyrosine kinase play important roles in mediating downstream cellular signals, and are potential targets for novel therapies. Using a functional proteomic approach, we determined the identity of proteins that interact with the ALK tyrosine kinase by co-immunoprecipitation with anti-ALK antibody, followed by electrospray ionization and tandem mass spectrometry (MS/MS). A total of 46 proteins were identified as unique to the ALK immunocomplex using monoclonal and polyclonal antibodies, while 11 proteins were identified in the NPM immunocomplex. Previously reported proteins in the ALK signal pathway were identified including PI3-K, Jak2, Jak3, Stat3, Grb2, IRS, and PLCĪ³1. More importantly, many proteins previously not recognized to be associated with NPM-ALK, but with potential NPM-ALK interacting protein domains, were identified. These include adaptor molecules (SOCS, Rho-GTPase activating protein, RAB35), kinases (MEK kinase 1 and 4, PKC, MLCK, cyclin G-associated kinase, EphA1, JNK kinase, MAP kinase 1), phosphatases (meprin, PTPK, protein phosphatase 2 subunit), and heat shock proteins (Hsp60 precursor). Proteins identified by MS were confirmed by Western blotting and reciprocal immunoprecipitation. This study demonstrates the utility of antibody immunoprecipitation and subsequent peptide identification by tandem mass spectrometry for the elucidation of ALK-binding proteins, and its potential signal transduction pathways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amin HM, Medeiros LJ, Ma Y, Feretzaki M, Das P, Leventaki V, Rassidakis GZ, O'Connor SL, McDonnell TJ and Lai R . (2003). Oncogene, 22, 5399ā5407.
Baba T, Fusaki N, Shinya N, Iwamatsu A and Hozumi N . (2003). Biochem. Biophys. Res. Commun., 304, 67ā72.
Bai RY, Dieter P, Peschel C, Morris SW and Duyster J . (1998). Mol. Cell. Biol., 18, 6951ā6961.
Bai RY, Ouyang T, Miething C, Morris SW, Peschel C and Duyster J . (2000). Blood, 96, 4319ā4327.
Bernhard OK, Burgess JA, Hochgrebe T, Sheil MM and Cunningham AL . (2003). Proteomics, 3, 139ā146.
Blagoev B, Kratchmarova I, Ong SE, Nielsen M, Foster LJ and Mann M . (2003). Nat. Biotechnol., 21, 315ā318.
Bonvini P, Gastaldi T, Falini B and Rosolen A . (2002). Cancer Res., 62, 1559ā1566.
Brazil DP, Park J and Hemmings BA . (2002). Cell, 111, 293ā303.
Davis TH, Morton CC, Miller-Cassman R, Balk SP and Kadin ME . (1992). N. Engl. J. Med., 326, 1115ā1122.
Edmondson RD, Vondriska TM, Biederman KJ, Zhang J, Jones RC, Zheng Y, Allen DL, Xiu JX, Cardwell EM, Pisano MR and Ping P . (2002). Mol. Cell. Proteomics, 1, 421ā433.
Epstein AL and Kaplan HS . (1974). Cancer, 34, 1851ā1872.
Figeys D, McBroom LD and Moran MF . (2001). Methods, 24, 230ā239.
Fischer P, Nacheva E, Mason DY, Sherrington PD, Hoyle C, Hayhoe FG and Karpas A . (1988). Blood, 72, 234ā240.
Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S and Yamamoto T . (1996). Proc. Natl. Acad. Sci. USA, 93, 4181ā4186.
Griffis ER, Xu S and Powers MA . (2003). Mol. Biol. Cell, 14, 600ā610.
Hubinger G, Scheffrahn I, Muller E, Bai R, Duyster J, Morris SW, Schrezenmeier H and Bergmann L . (1999). Exp. Hematol., 27, 1796ā1805.
Hubinger G, Wehnes E, Xue L, Morris SW and Maurer U . (2003). Exp. Hematol., 31, 226ā233.
Kai M, Tanaka H and Wang TS . (2001). Mol. Cell. Biol., 21, 3289ā3301.
Kaiser BK, Zimmerman ZA, Charbonneau H and Jackson PK . (2002). Mol. Biol. Cell, 13, 2289ā2300.
Kelkar N, Gupta S, Dickens M and Davis RJ . (2000). Mol. Cell. Biol., 20, 1030ā1043.
Khoury JD, Medeiros LJ, Rassidakis GZ, Yared MA, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin HM and Lai R . (2003). Clin. Cancer Res., 9, 3692ā3699.
Knaus PI, Lindemann D, DeCoteau JF, Perlman R, Yankelev H, Hille M, Kadin ME and Lodish HF . (1996). Mol. Cell. Biol., 16, 3480ā3489.
Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY and Morris SW . (1997). Blood, 90, 2901ā2910.
Luderus ME, de Graaf A, Mattia E, den Blaauwen JL, Grande MA, de Jong L and van Driel R . (1992). Cell, 70, 949ā959.
Lux A, Attisano L and Marchuk DA . (1999). J. Biol. Chem., 274, 9984ā9992.
Mason DY, Bastard C, Rimokh R, Dastugue N, Huret JL, Kristoffersson U, Magaud JP, Nezelof C, Tilly H and Vannier JP . (1990). Br. J. Haematol., 74, 161ā168.
Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A and Sakai R . (2002). Oncogene, 21, 5823ā5834.
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL and Look AT . (1994). Science, 263, 1281ā1284.
Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X and Witte DP . (1997). Oncogene, 14, 2175ā2188.
Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW and Skorski T . (2001). Cancer Res., 61, 6517ā6523.
Ohta S, Shiomi Y, Sugimoto K, Obuse C and Tsurimoto T . (2002). J. Biol. Chem., 277, 40362ā40367.
Pandey A, Lazar DF, Saltiel AR and Dixit VM . (1994). J. Biol. Chem., 269, 30154ā30157.
Payen E, Verkerk T, Michalovich D, Dreyer SD, Winterpacht A, Lee B, De Zeeuw CI, Grosveld F and Galjart N . (1998). J. Biol. Chem., 273, 9099ā9109.
Peng J, Elias JE, Thoreen CC, Licklider LJ and Gygi SP . (2003). J. Proteome Res., 2, 43ā50.
Pratt RL and Kinch MS . (2002). Oncogene, 21, 7690ā7699.
Raetz EA, Perkins SL, Carlson MA, Schooler KP, Carroll WL and Virshup DM . (2002). Am. J. Pathol., 161, 875ā883.
Ranish JA, Yi EC, Leslie DM, Purvine SO, Goodlett DR, Eng J and Aebersold R . (2003). Nat. Genet., 33, 349ā355.
Rashid KA, Hevi S, Chen Y, Le Caherec F and Chuck SL . (2002). J. Biol. Chem., 277, 22010ā22017.
Rey M, Vicente-Manzanares M, Viedma F, Yanez-Mo M, Urzainqui A, Barreiro O, Vazquez J and Sanchez-Madrid F . (2002). J. Immunol., 169, 5410ā5414.
Rossi L, Deri P, Andreoli I, Gremigni V, Salvetti A and Batistoni R . (2003). Int. J. Dev. Biol., 47, 293ā298.
Ruchatz H, Coluccia AM, Stano P, Marchesi E and Gambacorti-Passerini C . (2003). Exp. Hematol., 31, 309ā315.
Sharfe N, Freywald A, Toro A and Roifman CM . (2003). J. Immunol., 170, 6024ā6032.
Shiio Y, Donohoe S, Yi EC, Goodlett DR, Aebersold R and Eisenman RN . (2002). EMBO J., 21, 5088ā5096.
Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T and Mori S . (1994). Oncogene, 9, 1567ā1574.
Shiota M and Mori S . (1997). Leukemia, 11 (Suppl 3), 538ā540.
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC and Golub TR . (2002). Nat. Med., 8, 68ā74.
Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA and Skorski T . (2001). Cancer Res., 61, 2194ā2199.
Souttou B, Carvalho NB, Raulais D and Vigny M . (2001). J. Biol. Chem., 276, 9526ā9531.
Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R and Lennert K . (1985). Blood, 66, 848ā858.
Taimen P, Viljamaa M and Kallajoki M . (2000). Exp. Cell. Res., 256, 140ā149.
Tessier-Lavigne M . (1995). Cell, 82, 345ā348.
Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ and Kinch MS . (1999). Prostate, 41, 275ā280.
Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE and Inghirami G . (2002). Oncogene, 21, 1038ā1047.
Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS . (2001). Cancer Res., 61, 2301ā2306.
Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T and Wasik MA . (2002). J. Immunol., 168, 466ā474.
Acknowledgements
We thank Dr G Chris Fillmore for assistance with cell culture. This work was supported by the ARUP Institute for Clinical and Experimental Pathology.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Crockett, D., Lin, Z., Elenitoba-Johnson, K. et al. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 23, 2617ā2629 (2004). https://doi.org/10.1038/sj.onc.1207398
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207398
Keywords
This article is cited by
-
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
Oncogene (2020)
-
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
Leukemia (2014)
-
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Nature Reviews Cancer (2013)
-
Inhibition of Rac controls NPMāALK-dependent lymphoma development and dissemination
Blood Cancer Journal (2011)
-
Nucleophosmin deposition during mRNA 3ā² end processing influences poly(A) tail length
The EMBO Journal (2011)